HCW BIOLOGICS INC

HCW Biologics’ 1‑for‑6 reverse stock split preserves its Nasdaq listing, boosts share price to ~$6.18, and positions the biopharma firm for future growth.

HCW Biologics launches first‑in‑human trial of its IL‑2 fusion immunotherapy for alopecia areata, but faces high‑risk financial and competitive challenges.

HCW Biologics Inc. is a biopharmaceutical company focused on developing innovative immunotherapy treatments to address chronic inflammation and age-related diseases.

HCW Biologics Inc. has announced a $5 million follow-on offering, sparking a 16% surge in its stock price, as the company continues to pursue growth and innovation in the biopharmaceutical industry.